

**SUNESIS**

Pharmaceuticals, Inc.

11 December 2020

Sponsor: Sunesis Pharmaceuticals, Inc.
Protocol no.: 062-HEM-102
Protocol Title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
EudraCT no.: 2018-000108-41

To whom it may concern:

The 062-HEM-102 trial entitled "A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients with B-Lymphoid Malignancies" was terminated after completion of the Phase 1b portion. The trial was designed to study vecabrutinib (SNS-062), a noncovalent BTK inhibitor, in patients with B-cell malignancies that had developed resistance to prior covalent BTK inhibitor treatment. However, although safety was acceptable, the activity in BTK inhibitor-resistant disease was insufficient to progress into Phase 2. The Phase 1b was conducted in the US only and no patients were recruited or treated in the EU (Italy, France, Spain and UK).

Best regards,

Judith A. Fox, PhD
CSO, EVP R&D
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd.
South San Francisco, CA 94080
mobile:+1.415.336.2715